Close Menu

NEW YORK – Metastatic breast cancer patients with BRCA1/2 mutations who were treated with the combination of AstraZeneca's PARP inhibitor olaparib (Lynparza) and its checkpoint inhibitor durvalumab (Imfinzi) had similar response and stable disease rates as patients receiving these drugs as single agents, researchers reported recently in Lancet Oncology.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.